
Aloop Therapeutics ApS

CVR-no.: 43257498

Nordre Fasanvej 215
2000 Frederiksberg

Annual report
1 January 2024 - 31 December 2024

**The annual report has been presented and
approved on the company's general meeting
the**

16/05/2025

Søren Sylvester Skjærbæk
Chairman of general meeting

Content

Company informations

Company informations

Reports

Statement by Management

Management's Review

Management's Review

Financial statement

Income statement

Balance sheet

Disclosures

Company information

**Reporting
company**

Aloop Therapeutics ApS

Nordre Fasanvej 215

2000 Frederiksberg

CVR-no.: 43257498

Reporting
period: 01/01/2024 - 31/12/2024

Statement by Management

Today, the management has considered and approved the annual report for the financial period 01 January 2024 - 31 December 2024 for Aloop Therapeutics ApS.

The annual report is presented in accordance with the Danish Financial Statements Act.

It is the management's opinion that the annual accounts give a true and fair view of the company's assets, liabilities and financial position as well as of the result.

The annual report is recommended for approval by the general meeting.

Management considers the conditions for opting out of audit to be met.

, the

Management

Rodolphe Clerval
CEO

Management's Review

Effective as of 31 December 2024, the company had no significant activities.

The gross loss for the year totals DKK -1.323.042 against DKK -9.058.291 last year. Loss from ordinary activities after tax totals DKK -1.295.153 against DKK -8.808.915 last year. Management finds the net loss for the year as expected.

Events occurring after the end of the financial year: No events have occurred subsequent to the balance sheet date, which would have material impact on the financial position of the company.

Income statement 1 Jan 2024 - 31 Dec 2024

	Disclosure	2024 DKK	2023 DKK
Gross profit (loss)		-1,323,042	-9,058,291
Employee expense		-1,437,099	-2,845,933
Wages and salaries			-2,838,183
Social security contributions			-7,750
Depreciation, amortisation expense and impairment losses of property, plant and equipment and intangible assets		0	
Profit (loss) from ordinary operating activities		-2,760,141	-11,904,224
Other finance income		856,657	384,511
Other finance expenses			-4,449
Profit (loss) from ordinary activities before tax		-1,903,484	-11,524,162
Tax expense		608,331	2,715,247
Profit (loss)		-1,295,153	-8,808,915
Proposed distribution of results			
Retained earnings		-1,295,153	-8,808,915
Proposed distribution of profit (loss)		-1,295,153	-8,808,915

Balance sheet 31 December 2024

Assets

	Disclosure	2024	2023
		DKK	DKK
Deposits		0	6,741
Investments		0	6,741
Total non-current assets		0	6,741
Raw materials and consumables		0	
Manufactured goods and goods for resale		0	
Inventories		0	
Receivables from group enterprises		608,331	2,701,174
Other receivables		14,507	731,221
Receivables		622,838	3,432,395
Cash and cash equivalents		30,191,188	30,810,955
Current assets		30,814,026	34,243,350
TOTAL ASSETS		30,814,026	34,250,091

Balance sheet 31 December 2024

Liabilities and equity

	Disclosure	2024	2023
		DKK	DKK
Contributed capital		300,000	300,000
Retained earnings		30,427,192	31,722,337
Total equity		30,727,192	32,022,337
Trade payables		86,834	1,609,286
Other payables, including tax payables, liabilities other than provisions			618,468
Short-term liabilities other than provisions, gross		86,834	2,227,754
Liabilities other than provisions, gross		86,834	2,227,754
LIABILITIES AND EQUITY, GROSS		30,814,026	34,250,091

Disclosures

1. Disclosure of application of exceptions for micro-undertakings

The micro-undertaking applies the exception concerning filing information about accounting policies

The micro-undertaking applies the exception concerning filing information about number of employees